CheckMate 8HW
01 Jul 2019
CA209-8HW
NCT04008030
A Phase 3 Randomized Clinical Trial of Nivolumab Alone, Nivolumab in Combination With Ipilimumab, or an Investigator’s Choice Chemotherapy in Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer
Bristol-Myers Squibb
Cancer Type | Bowel |
---|---|
Trial Type | Treatment |
Phase | Phase II |
Age Range | 18+ years |
Sex | All |
Tumour Stream | Colorectal cancer |
Cancer Stage | Locally Recurrent or Locally Advanced, Matastatic or Widespread |
Anticipated Start Date | 2019-07-29 |
Anticipated End Date | 2025-07-05 |
Hospital | Calvary Central Districts Hospital |
---|---|
Clinical Trial Coordinator | Julie Rowe |
julie.rowe@calvarycare.org.au | |
Phone | 08 8239 9536 |
Principal Investigator | Dr Rohit Joshi |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs